Helse Bergen HF — Sponsor Intelligence | 26 EU Trials

Filter these 26 trials by condition, phase, country and more.

Open in Search →

26 Registered trials

12 Recruiting

10 Completed trials

4 Countries active

49 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 8 Phase II/III: 1 Phase II: 12 Phase I/II: 1 Phase III/IV: 1 Phase IV: 2 Phase I (FiH): 1

Oversight events:

2 serious breaches 1 urgent safety measure across 3 trials

View oversight register →

100%

10 of 10 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Breast cancer 1 Relapsing-remitting multiple sclerosis 1 Multiple sclerosis 1 Malignant glioma 1

Top IMPs

CYCLOPHOSPHAMIDE 2 DARATUMUMAB 2 DIAZEPAM 2 OCRELIZUMAB 2 PERFLUBUTANE 2 TENOFOVIR ALAFENAMIDE 2 ALEMTUZUMAB 1 ANTITHYMOCYTE IMMUNOGLOBULIN 1 BORTEZOMIB 1 BUSPIRONE HYDROCHLORIDE 1 CLADRIBINE 1 CORTISONE 1

All trials

26 total

Episodic CandClus2: A randomized, placebo-controlled, triple blind study of candesartan in adults with episodic cluster headache Pending

2025-521470-34-00 Phase III 2 countries
Chronic CandClus2: A randomized, placebo-controlled, triple blind crossover study of candesartan in adults with chronic cluster headache Pending

2025-521529-34-00 Phase III 2 countries
The DELTA-EBV study Pending

2025-522781-77-01 Phase II 1 country TENOFOVIR ALAFENAMIDE
CNS penetration and target engagement of Mirivadelgat in Parkinson’s disease Pending

2025-523570-17-00 Phase II 1 country MIRIVADELGAT
SonoDOCc 2 Recruiting

2023-508500-38-00 Phase II 1 country PERFLUBUTANE; SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SO…
Metycor study Recruiting

2024-514143-28-00 Phase IV 1 country METYRAPONE
Plasma cell targeting in ME/CFS Recruiting

2024-520094-13-00 Phase II 1 country DARATUMUMAB; HYALURONIDASE
An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabo… Recruiting

2023-506109-20-00 Phase III 1 country SEMAGLUTIDE
BORTEM 17 Recruiting

2024-515142-16-00 Phase I (FiH) 1 country BORTEZOMIB; TEMOZOLOMIDE
Dextroamphetamine Substitution for Amphetamines Dependence: A Randomized Controlled Trial Recruiting

2023-508291-11-00 Phase II 1 country DEXAMFETAMINE SULFATE
Prospective comparison of sirolimus against corticosteroids in treatment of patients with active thyroid eye disease Recruiting

2023-510166-27-01 Phase III 1 country METHYLPREDNISOLONE; SIROLIMUS
A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercapto… Recruiting

2022-501992-15-00 Phase I/II 1 country
SMART-MS Recruiting

2023-510228-63-00 Phase II 1 country MESENCHYMAL STROMAL CELLS, EX VIVO CULTURED; SODIUM CHLORIDE
The CORTAD study Recruiting

2024-512888-31-00 Phase III/IV 1 country CORTISONE; HYDROCORTISONE
Benzodiazepine stabilizing treatment for patients with benzodiazepine dependence undergoing opioid agonist therapy (BMX-BAR) Recruiting

2023-510404-44-02 Phase III 1 country DIAZEPAM; OXAZEPAM
Efficacy of Hyperbaric oxygen in addition to standard treatment for acute sudden deafness Recruiting

2024-510798-84-00 Phase II/III 1 country
Immunogenicity of Licensed zoonotic influenza vaccine in primed and naive participants. Ended

2025-522593-36-00 Phase IV 1 country INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8)-LIKE STRAIN (CBER-RG8A) (CLADE 2.3.4.4B)
PErsonalized TREatment of high-risk MAmmary Cancer - the PETREMAC trial Ended

2024-519364-40-00 Phase II 1 country OLAPARIB; PALBOCICLIB; PERTUZUMAB
The p53 breast cancer trial Ended

2024-515135-29-00 Phase II 1 country CYCLOPHOSPHAMIDE
The role of sonoporation-enhanced treatment in patients with inoperable pancreatic cancer Ended

2024-512176-35-00 Phase II 1 country FLUOROURACIL; FOLINIC ACID; GEMCITABINE HYDROCHLORIDE; IRINOTECAN HYDROCHLORIDE …
Antiviral treatment for long covid. Ended

2023-510337-29-00 Phase III 1 country
Daratumumab in ME/CFS Ended

2024-512500-19-00 Phase II 1 country DARATUMUMAB
Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Ended

2024-510716-71-00 Phase III 2 countries OCRELIZUMAB; RITUXIMAB
RAM-MS Ended

2024-510630-40-00 Phase III 4 countries ALEMTUZUMAB; ANTITHYMOCYTE IMMUNOGLOBULIN; CLADRIBINE; CYCLOPHOSPHAMIDE; OCRELIZ…

Showing 1–24 of 26 trials

← All sponsors A–Z